Alentis will collaborate with the FHNW School of Life Sciences to identify translational biomarkers of Claudin-1 for use in future Alentis trialsBasel, Switzerland – 27 September 2022 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announced the Swiss Innovation Agency, Innosuisse, will co-fund a research collaboration with the FHNW School of Life Sciences to accelerate the discovery of Claudin-1-associated biomarkers for fibrosis.Claudin-1 (CLDN1) is a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of organ fibrosis and fibrotic…

Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment ofLiver and Kidney Fibrosis FDA greenlights Alentis Phase 1 protocol study designAlentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 -- Alentis Therapeutics, AG today announced it has dosed the first cohort of healthy participants in a first-in-human Phase 1 clinical trial of ALE.F02, a monoclonal antibody highly selective for Claudin-1, currently being developed for the treatment of advanced unmet liver and kidney fibrosis. Alentis is a clinical stage biopharma focused on discovering and developing novel therapies for the treatment of unmet fibrotic diseases. "ALE.F02 has…

Alentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaèle Tordjman as Chairperson Basel, Switzerland – 9 November 2021 Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today the appointments of Luca Santarelli, M.D. as independent Non-Executive Director, and Rafaèle Tordjman, M.D. PhD as Chairperson of its Board of Directors, with immediate effect.Dr. Roberto Iacone, Chief Executive Officer of Alentis Therapeutics, commented: “Luca is a highly experienced entrepreneur in the life sciences sector and his successful track record in driving drug programs from discovery to commercialization will be invaluable as we…

BASEL, Switzerland -- (01 November 2021) Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Alberto Toso has joined the team as Head of Oncology, effective this month. “I‘m truly excited to continue my fight against cancer at Alentis. I believe the team has the potential to deliver transformative drugs that cancer patients need so urgently.” Welcoming Mr. Toso to the company, Dr. Roberto Iacone, CEO of Alentis said, “Alberto is a tremendous addition to our team with innovative leadership, very deep expertise in Oncology and unwavering commitment to fight cancer.” Alberto brings more…

BASEL, Switzerland -- (19 October 2021) Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Geoffrey Teixeira has joined the team as Head of Fibrosis. Geoffrey brings more than 9 years of industrial drug development experience in inflammatory and fibrotic diseases. He was most recently Translational Research Lead of Fibrosis at Galapagos, Mechelen, Belgium. At Galapagos he was responsible for leading translational activities for the company’s fibrosis pipeline, and for reverse translation activities and platform development, combining multi-omics and machine learning approaches for the identification of new targets and biomarkers. Prior to Galapagos, Geoffrey…

Basel, June 23, 2021 – Alentis Therapeutics today announced that it will present  data at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2021, being held virtually from June 23-26, 2021.Click here to read full press release

About: Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round. The funding will be used primarily for proof-of-concept clinical trials of Alentis’ first-in-class, Claudin-1 targeting, anti-fibrotic molecules in advanced liver and kidney fibrosis, and support ongoing drug discovery programs targeting other fibrotic diseases and hepatobiliary cancers. Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital. Alentis welcomes Jason Dinges of Morningside…

Basel, Switzerland, December 23, 2020 – Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Prof. Thomas Baumert, its founder and world-leading authority in the field, has been awarded the Mémain-Pelletier, French Academy of Science award for his ground-breaking research into understanding the pathogenesis of liver cancer. Said Prof. Thomas Baumert: “It’s a great honor and a mark of recognition for my team, my colleagues and collaborators, some 50 in all. Now we are going to have to redouble our efforts, with a view to bringing our research to patients so they can truly…

Basel, Switzerland, July 29, 2020 – Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Dr. Roberto Iacone, has been named Chief Executive Officer. Dr. Iacone is a physician-scientist, a serial entrepreneur and brings more than 15 years life science industry experience to Alentis. Most recently while at Versant Ventures, he co-founded Bright Peak Therapeutics and Ridgeline Therapeutics, and was part of the leadership team that built the precision oncology company Black Diamond Therapeutics from inception through to its NASDAQ IPO in three years.  Prior to Versant, Roberto was Roche's Global Head of Rare Diseases Research, where he established numerous collaborations with academic and…

ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer Basel, April 30, 2019. ALENTIS Therapeutics (“ALENTIS”), a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the round and were joined by Bpifrance, Schroder Adveq and the German High-Tech Gründerfonds (HTGF). Markus L.E. Ewert, PhD, MBA has joined the company as Chief Executive Officer. Markus was previously CBO…